NCT06825624View on ClinicalTrials.gov

ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer

PHASE1RecruitingINTERVENTIONAL

Enrollment

560

Participants

Timeline

Start Date

October 3, 2024

Primary Completion Date

October 31, 2026

Study Completion Date

December 31, 2026

Conditions

Metastatic Colorectal Cancer (CRC)

Interventions

DRUG

HS-20093

administered as an IV infusion

DRUG

Bevacizumab

administered as an IV infusion

DRUG

5-FU

administered as an IV infusion

DRUG

Leucovorin

administered as an IV infusion

DRUG

Capecitabine

administered orally

DRUG

Oxaliplatin

administered as an IV infusion

Trial Locations (1)

Unknown

RECRUITING

The Second Affiliated Hospital Zhejiang University, Hangzhou

All Listed Sponsors

lead

Hansoh BioMedical R&D Company

INDUSTRY